Clinical trials

Main clinical trials:

"A randomized,open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST)".

"A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate."

" Studio Infinity:IPI-504-06, A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Following Failure of at Least Imatinib and Sunitinib".
Sponsor Infinity. Open soon.

"A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's chioice) in adult patients with gastrointetsinal stromal tumors resistant to both imatinib and sunitinib".
Sponsor Novartis. Just closed.

"Intermediate and high-risk localised, completely resected, gastro-intestinal stromal tumours (GIST) expressing c-kit receptor: A controlled randomised trial on adjuvant imatinib mesylate (Glivec®) versus no further therapy after completing surgery". Sponsor Novartis. Open.

"A Phase III, Randomized, ACTIVE Controlled OPEN-LABEL STudy of Sunitinib (SU011248) 37.5 mg daily vs Imatinib Mesylate 800 mg daily in the Treatment of Patients WITH Gastrointestinal Stromal Tumors (GIST) who have had progressive disease while on 400 MG Daily of Imatinib".
Sponsor Pfizer. Open.

“A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Glivec) Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor”. Sponsor Pfizer. Closed.

“A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate”. Sponsor Pfizer. Open.

“The Global Observational registry collecting Longitudinal-Data on advanced GIST patients” (diagnosed within 15 months prior to registry entry with:
-Initial diagnosis of unresectable GIST or
-recurrence of previously resected GIST and/or
-metastatic GIST). Sponsor Novartis. Open.